MBX Biosciences pushes canvuparatide to full Phase III enrollment, eyes Q4 obesity data
The company told a Morgan Stanley healthcare conference that once-monthly candidate MBX 4291 has key data due in the fourth quarter.
TR
By Tom Reyes · Markets Editor
Sep 16 09:51 ETSource: TradingView
The wire
- 01At the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 16, MBX leadership said canvuparatide is advancing to full Phase III enrollment with commercialization preparation underway.
- 02MBX 4291 is positioned as a once-monthly obesity treatment, a dosing interval that would sit apart from weekly incretin injections clinicians now prescribe.
- 03Two further obesity candidates are targeted for INDs by 2027; the remarks are company statements from a conference transcript, not published data.
From the source
Read at tradingview.comMBX: Advancing late-stage peptide therapies with pivotal data and new obesity candidates expected by 2027
Leadership is focused on advancing canvuparatide to full phase III enrollment and preparing for commercialization, while MBX 4291 targets once-monthly obesity treatment with key data expected in Q4. The platform supports a robust pipeline, with two new obesity candidates aiming for INDs by 2027.